2024
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55: 6. PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsFemaleHumansMolecular Targeted TherapyMutationPrecision MedicineConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutations
2022
Gene expressions and their significance in organoid cultures obtained from breast cancer patient-derived biopsies
Pranav P, Palaniyandi T, Baskar G, Ravi M, Rajendran B, Sivaji A, Ranganathan M. Gene expressions and their significance in organoid cultures obtained from breast cancer patient-derived biopsies. Acta Histochemica 2022, 124: 151910. PMID: 35667159, DOI: 10.1016/j.acthis.2022.151910.Peer-Reviewed Original ResearchConceptsBreast cancerOrganoid culturesGene expression changesPatient-derived biopsiesBreast cancer biopsiesExpression of ErbB2Progesterone receptor geneCancer cell linesExpression changesSuch cancersPatient biopsiesCancer biopsiesSolid tumorsBiopsyMalignant cellsCancerGene expressionMagnitude of expressionHuman cancersCancer therapyReceptor geneCell linesSuch organoidsCancer researchFunctional physiology
2021
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics
Ding R, Chen P, Rajendran B, Lyu X, Wang H, Bao J, Zeng J, Hao W, Sun H, Wong A, Valecha M, Yang E, Su S, Choi T, Liu S, Chan K, Yang L, Wu J, Miao K, Chen Q, Shim J, Xu X, Deng C. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nature Communications 2021, 12: 3046. PMID: 34031426, PMCID: PMC8144567, DOI: 10.1038/s41467-021-23379-3.Peer-Reviewed Original ResearchConceptsSarcomatoid carcinomaEpithelial-mesenchymal transitionNasopharyngeal carcinomaCarcinoma subtypesNeck cancer typesPatient-derived organoidCRT regimensDistinct molecular featuresMalignant headHigh morbidityTreatment regimensTherapeutic responseEC subtypesPathogenic mechanismsDrug responsivenessEGFR inhibitorsNPC subtypesCancer typesSubtypesCarcinomaPrecision oncologyDrug testsMolecular landscapeRegimensMicrotubule inhibitorsAccelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform
Xing F, Liu Y, Huang S, Lyu X, Su S, Chan U, Wu P, Yan Y, Ai N, Li J, Zhao M, Rajendran B, Liu J, Shao F, Sun H, Choi T, Zhu W, Luo G, Liu S, Xu D, Chan K, Zhao Q, Miao K, Luo K, Ge W, Xu X, Wang G, Liu T, Deng C. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics 2021, 11: 9415-9430. PMID: 34646378, PMCID: PMC8490519, DOI: 10.7150/thno.59533.Peer-Reviewed Original ResearchConceptsAnti-cancer therapyNew pre-clinical modelsDay of surgeryPre-clinical modelsRNA sequence analysisHigh-efficacy drugsAnti-cancer drug efficacyPD-1PD-L1Personalized medicineBlockade assayAnti-cancer drug discoveryImmune componentsOriginal tumorAutofluorescence featuresDrug efficacyHistological analysisPrecision anti-cancer therapyCancer treatmentDrug responseHigh-throughput drug screeningDrug discoveryTherapyEfficacyCell-based high-throughput drug screening